Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Lake Street Sticks to Its Buy Rating for Arcadia Biosciences (RKDA)

Tipranks - Tipranks - Tue Aug 19, 2025

Lake Street analyst Ben Klieve maintained a Buy rating on Arcadia Biosciences on August 15 and set a price target of $12.00. The company’s shares closed last Friday at $4.65.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Klieve covers the Consumer Defensive sector, focusing on stocks such as MGP Ingredients, Vital Farms, and Lifeway Foods. According to TipRanks, Klieve has an average return of 3.5% and a 44.79% success rate on recommended stocks.

Arcadia Biosciences has an analyst consensus of Hold, with a price target consensus of $4.50.

See Insiders’ Hot Stocks on TipRanks >>

Based on Arcadia Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $1.2 million and a net profit of $2.6 million. In comparison, last year the company earned a revenue of $1.26 million and had a GAAP net loss of $2.42 million

Read More on RKDA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).